|
| Status |
Public on Nov 01, 2023 |
| Title |
The Triptryium wilfordii derivative celastrol has anti-fibrotic effects in systemic sclerosis |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
Other
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
37328193 |
| |
| Submission date |
Mar 01, 2023 |
| Last update date |
Jan 31, 2024 |
| Contact name |
Andrew Leask |
| E-mail(s) |
[email protected]
|
| Organization name |
University of Saskatchewan
|
| Department |
College of Dentistry
|
| Lab |
Leask Lab
|
| Street address |
105 Wiggins
|
| City |
Saskatoon |
| State/province |
Saskatchewan |
| ZIP/Postal code |
S7N5E4 |
| Country |
Canada |
| |
|
| Platforms (2) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
| GPL19057 |
Illumina NextSeq 500 (Mus musculus) |
|
| Samples (24)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE226374 |
The Triptryium wilfordii derivative celastrol has anti-fibrotic effects in systemic sclerosis [in vitro bulk RNA-seq] |
| GSE226375 |
The Triptryium wilfordii derivative celastrol has anti-fibrotic effects in systemic sclerosis [In vivo bulk RNA-seq] |
| GSE226760 |
The Triptryium wilfordii derivative celastrol has anti-fibrotic effects in systemic sclerosis [Spatial Transcriptomics] |
|
| Relations |
| BioProject |
PRJNA940081 |
Less...
More...